BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 You W, Xu Z, Di A, Liu P, Pang C, Wang J, Li X, Wang Y, Yu B, Liu X, Zhao G. Mechanism by Which Tong Xie Yao Fang Heals the Intestinal Mucosa of Rats with Ulcerative Colitis through the Hippo Pathway. Evid Based Complement Alternat Med 2021;2021:5533914. [PMID: 34504536 DOI: 10.1155/2021/5533914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Sun L, Ouyang J, Zeng F, Wu S. An AIEgen-based oral-administration nanosystem for detection and therapy of ulcerative colitis via 3D-MSOT/NIR-II fluorescent imaging and inhibiting NLRP3 inflammasome. Biomaterials 2022;283:121468. [DOI: 10.1016/j.biomaterials.2022.121468] [Reference Citation Analysis]
3 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Reference Citation Analysis]
4 Ray MK, Fenton CG, Paulssen RH. Novel long non-coding RNAs of relevance for ulcerative colitis pathogenesis. Non-coding RNA Research 2022;7:40-7. [DOI: 10.1016/j.ncrna.2022.02.001] [Reference Citation Analysis]
5 Liu C, Yan X, Zhang Y, Yang M, Ma Y, Zhang Y, Xu Q, Tu K, Zhang M. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. J Nanobiotechnology 2022;20:206. [PMID: 35488343 DOI: 10.1186/s12951-022-01421-w] [Reference Citation Analysis]
6 Wu X, Chen H, Gao X, Gao H, He Q, Li G, Yao J, Liu Z. Natural Herbal Remedy Wumei Decoction Ameliorates Intestinal Mucosal Inflammation by Inhibiting Th1/Th17 Cell Differentiation and Maintaining Microbial Homeostasis. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab348] [Reference Citation Analysis]
7 Gu L, Ren F, Fang X, Yuan L, Liu G, Wang S. Exosomal MicroRNA-181a Derived From Mesenchymal Stem Cells Improves Gut Microbiota Composition, Barrier Function, and Inflammatory Status in an Experimental Colitis Model. Front Med (Lausanne) 2021;8:660614. [PMID: 34249964 DOI: 10.3389/fmed.2021.660614] [Reference Citation Analysis]
8 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Matsuoka K, Nagano K, Nagasaki S, Murata Y, Hisamatsu T. Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study. BMJ Open 2022;12:e060081. [PMID: 35508346 DOI: 10.1136/bmjopen-2021-060081] [Reference Citation Analysis]
10 Rui X, Li J, Yang Y, Xu L, Liu Y, Zhang M, Yin D. Painong San, a Traditional Chinese Compound Herbal Medicine, Restores Colon Barrier Function on DSS-Induced Colitis in Mice. Evid Based Complement Alternat Med 2021;2021:2810915. [PMID: 34966434 DOI: 10.1155/2021/2810915] [Reference Citation Analysis]
11 Yang Y, Han Z, Li X, Huang A, Shi J, Gu J. Epidemiology and risk factors of colorectal cancer in China. Chin J Cancer Res 2020;32:729-41. [PMID: 33446996 DOI: 10.21147/j.issn.1000-9604.2020.06.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Manouchehri N, Stüve O. Choroid plexus volumetrics and brain inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2021;118:e2115221118. [PMID: 34583997 DOI: 10.1073/pnas.2115221118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ruan J, Schlüter D, Naumann M, Waisman A, Wang X. Ubiquitin-modifying enzymes as regulators of colitis. Trends Mol Med 2022:S1471-4914(22)00025-9. [PMID: 35177326 DOI: 10.1016/j.molmed.2022.01.006] [Reference Citation Analysis]
14 Qi L, Wu J, Zhu S, Wang X, Lv X, Liu C, Liu YJ, Chen J. Mesenchymal Stem Cells Alleviate Inflammatory Bowel Disease Via Tr1 Cells. Stem Cell Rev Rep 2022. [PMID: 35274217 DOI: 10.1007/s12015-022-10353-9] [Reference Citation Analysis]
15 Chen K, Lou Y, Zhu Y. Tong Xie Yao Fang: A Classic Chinese Medicine Prescription with Potential for the Treatment of Ulcerative Colitis. Evid Based Complement Alternat Med 2021;2021:5548764. [PMID: 34211567 DOI: 10.1155/2021/5548764] [Reference Citation Analysis]
16 Mao Q, Pan H, Zhang Y, Zhang Y, Zhu Q, Hong Y, Huang Z, Li Y, Feng X, Fang Y, Chen W, Chen P, Shen B, Ouyang H, Liang Y. GelNB molecular coating as a biophysical barrier to isolate intestinal irritating metabolites and regulate intestinal microbial homeostasis in the treatment of inflammatory bowel disease. Bioactive Materials 2023;19:251-67. [DOI: 10.1016/j.bioactmat.2022.04.001] [Reference Citation Analysis]
17 Madsen GR, Bertl K, Pandis N, Stavropoulos A, Burisch J. The Impact of Periodontitis on Inflammatory Bowel Disease Activity. Inflamm Bowel Dis 2022:izac090. [PMID: 35552410 DOI: 10.1093/ibd/izac090] [Reference Citation Analysis]
18 Ouyang J, Sun L, Pan J, Zeng Z, Zeng C, Zeng F, Tian M, Wu S. A Targeted Nanosystem for Detection of Inflammatory Diseases via Fluorescent/Optoacoustic Imaging and Therapy via Modulating Nrf2/NF-κB Pathways. Small 2021;17:e2102598. [PMID: 34523220 DOI: 10.1002/smll.202102598] [Reference Citation Analysis]
19 Bamias G, Kokkotis G, Gizis M, Kapizioni C, Karmiris K, Koureta E, Kyriakos N, Leonidakis G, Makris K, Markopoulos P, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Siakavellas SI, Triantafyllou K, Tsironi E, Tsoukali E, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Zografos K, Papatheodoridis G, Mantzaris G. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Dig Dis Sci 2021. [PMID: 33751325 DOI: 10.1007/s10620-021-06907-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Matsuoka K, Ishikawa H, Nakayama T, Honzawa Y, Maemoto A, Hirai F, Ueno F, Sato N, Susuta Y, Hibi T. Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. J Gastroenterol 2021;56:843-55. [PMID: 34313863 DOI: 10.1007/s00535-021-01811-1] [Reference Citation Analysis]
21 Zhu J, Xin M, Xu C, He Y, Zhang W, Wang Z, Zhuang C. Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy. Acta Pharmaceutica Sinica B 2021. [DOI: 10.1016/j.apsb.2021.05.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Li M, Yang L, Mu C, Sun Y, Gu Y, Chen D, Liu T, Cao H. Gut Microbial Metabolome in Inflammatory Bowel Disease: from Association to Therapeutic Perspectives. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.03.038] [Reference Citation Analysis]
23 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
24 Hu H, Lei Y, Zhang W, Xiong P, Song L, Luo X, Jia B, Zhang F. Anti-inflammatory activity and safety of compound glycyrrhizin in ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials. Journal of Functional Foods 2022;91:105004. [DOI: 10.1016/j.jff.2022.105004] [Reference Citation Analysis]
25 Hu Y, Ye Z, She Y, Li L, Wu M, Qin K, Li Y, He H, Hu Z, Yang M, Lu F, Ye Q. Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Front Pharmacol 2022;13:844961. [DOI: 10.3389/fphar.2022.844961] [Reference Citation Analysis]
26 Tang K, Wu Z, Sun M, Huang X, Sun J, Shi J, Wang X, Miao Z, Gao P, Song Y, Wang Z. Elevated MMP10/13 mediated barrier disruption and NF-κB activation aggravate colitis and colon tumorigenesis in both individual or full miR-148/152 family knockout mice. Cancer Lett 2022;529:53-69. [PMID: 34979166 DOI: 10.1016/j.canlet.2021.12.033] [Reference Citation Analysis]
27 Liu J, Liu J, Tong X, Peng W, Wei S, Sun T, Wang Y, Zhang B, Li W. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis. Drug Des Devel Ther 2021;15:3255-76. [PMID: 34349502 DOI: 10.2147/DDDT.S319786] [Reference Citation Analysis]
28 Gu W, Zhang L, Han T, Huang H, Chen J. Dynamic Changes in Gut Microbiome of Ulcerative Colitis: Initial Study from Animal Model. JIR 2022;Volume 15:2631-47. [DOI: 10.2147/jir.s358807] [Reference Citation Analysis]
29 Liu B, Zheng X, Li J, Li X, Wu R, Yang J, Liu W, Zhao G. Revealing mechanism of Caulis Sargentodoxae for the treatment of ulcerative colitis based on network pharmacology approach. Biosci Rep 2021;41:BSR20204005. [PMID: 33432986 DOI: 10.1042/BSR20204005] [Reference Citation Analysis]
30 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
31 Li X, Lv H, Shi F, Song J, Zhang Z. The potential therapeutic effects of hydroxypropyl cellulose on acute murine colitis induced by DSS. Carbohydrate Polymers 2022;289:119430. [DOI: 10.1016/j.carbpol.2022.119430] [Reference Citation Analysis]
32 Hendel SK, Kellermann L, Hausmann A, Bindslev N, Jensen KB, Nielsen OH. Tuft Cells and Their Role in Intestinal Diseases. Front Immunol 2022;13:822867. [DOI: 10.3389/fimmu.2022.822867] [Reference Citation Analysis]
33 Ali FEM, M Elfiky M, Fadda WA, Ali HS, Mahmoud AR, Mohammedsaleh ZM, Abd-Elhamid TH. Regulation of IL-6/STAT-3/Wnt axis by nifuroxazide dampens colon ulcer in acetic acid-induced ulcerative colitis model: Novel mechanistic insight. Life Sci 2021;276:119433. [PMID: 33794250 DOI: 10.1016/j.lfs.2021.119433] [Reference Citation Analysis]
34 Yi YS. Dual roles of the caspase-11 non-canonical inflammasome in inflammatory bowel disease. Int Immunopharmacol 2022;108:108739. [PMID: 35366642 DOI: 10.1016/j.intimp.2022.108739] [Reference Citation Analysis]
35 Olbei M, Thomas JP, Hautefort I, Treveil A, Bohar B, Madgwick M, Gul L, Csabai L, Modos D, Korcsmaros T. CytokineLink: A Cytokine Communication Map to Analyse Immune Responses-Case Studies in Inflammatory Bowel Disease and COVID-19. Cells 2021;10:2242. [PMID: 34571891 DOI: 10.3390/cells10092242] [Reference Citation Analysis]
36 Xu X, Luo A, Lu X, Liu M, Wang H, Song H, Wei C, Wang Y, Duan X. p-Hydroxybenzoic acid alleviates inflammatory responses and intestinal mucosal damage in DSS-induced colitis by activating ERβ signaling. Journal of Functional Foods 2021;87:104835. [DOI: 10.1016/j.jff.2021.104835] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis 2021:izab062. [PMID: 33847348 DOI: 10.1093/ibd/izab062] [Reference Citation Analysis]
38 Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proc Natl Acad Sci U S A 2021;118:e2024853118. [PMID: 34253611 DOI: 10.1073/pnas.2024853118] [Reference Citation Analysis]
39 Fernandes SA, Rossoni C, Koch VW, Imbrizi M, Evangelista-Poderoso R, Pinto LP, Magro DO. Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease. Artif Intell Gastroenterol 2021; 2(4): 111-123 [DOI: 10.35712/aig.v2.i4.111] [Reference Citation Analysis]
40 Li R, Cheng L, Wang Q, Zhou L. Comparative Transcriptomic Analysis Reveals the Immunosuppressive Targets of Mesalazine in Dextran Sulfate Sodium-Induced Ulcerative Colitis. Front Genet 2021;12:698983. [PMID: 34456974 DOI: 10.3389/fgene.2021.698983] [Reference Citation Analysis]
41 Qiu P, Liu L, Fang J, Zhang M, Wang H, Peng Y, Chen M, Liu J, Wang F, Zhao Q. Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis. Front Pharmacol 2021;12:769718. [PMID: 34925026 DOI: 10.3389/fphar.2021.769718] [Reference Citation Analysis]
42 Guo J, Liao M, Zhu Y, Hu X, Wang J. The protective role of Chitooligosaccharides against chronic ulcerative colitis induced by dextran sulfate sodium in mice. Journal of Functional Foods 2021;87:104809. [DOI: 10.1016/j.jff.2021.104809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Duus KS, Moos C, Frederiksen P, Andersen V, Heitmann BL. Prenatal and Early Life Exposure to the Danish Mandatory Vitamin D Fortification Policy Might Prevent Inflammatory Bowel Disease Later in Life: A Societal Experiment. Nutrients 2021;13:1367. [PMID: 33921832 DOI: 10.3390/nu13041367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751. [PMID: 34902790 DOI: 10.1016/j.ebiom.2021.103751] [Reference Citation Analysis]
45 Albayrak NE, Polydorides AD. Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation. Am J Surg Pathol 2022. [PMID: 35354161 DOI: 10.1097/PAS.0000000000001883] [Reference Citation Analysis]
46 Chen X, Li X, Sun-Waterhouse D, Zhu B, You L, Hileuskaya K. Polysaccharides from Sargassum fusiforme after UV/H2O2 degradation effectively ameliorate dextran sulfate sodium-induced colitis. Food Funct 2021;12:11747-59. [PMID: 34806724 DOI: 10.1039/d1fo02708e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Reference Citation Analysis]
48 Xie Q, Li H, Ma R, Ren M, Li Y, Li J, Chen H, Chen Z, Gong D, Wang J. Effect of Coptis chinensis franch and Magnolia officinalis on intestinal flora and intestinal barrier in a TNBS-induced ulcerative colitis rats model. Phytomedicine 2022;97:153927. [PMID: 35030387 DOI: 10.1016/j.phymed.2022.153927] [Reference Citation Analysis]
49 Tian L, Zhao JL, Kang JQ, Guo SB, Zhang N, Shang L, Zhang YL, Zhang J, Jiang X, Lin Y. Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling. Front Immunol 2021;12:740565. [PMID: 34589089 DOI: 10.3389/fimmu.2021.740565] [Reference Citation Analysis]
50 Qu B, Cao T, Wang M, Wang S, Li W, Li H. Ginsenosides Rd monomer inhibits proinflammatory cytokines production and alleviates DSS-colitis by NF-κB and P38MAPK pathways in mice. Immunopharmacol Immunotoxicol 2021;:1-9. [PMID: 34898349 DOI: 10.1080/08923973.2021.2012482] [Reference Citation Analysis]
51 Li B, Li H, Zhu Z, Xiang C, Xu Z, Fan C, Zhao Y, Feng C, Sun H, Zhang Y, Cai T, Tang W, Zhu W. Discovery of chiral N-2'-aryletheryl-1'-alkoxy-ethyl substituted arylisoquinolones with anti-inflammatory activity from the nucleophilic addition reactions of the thiophenols and oxazolinium. Eur J Med Chem 2021;222:113583. [PMID: 34119832 DOI: 10.1016/j.ejmech.2021.113583] [Reference Citation Analysis]
52 Xue G, Gao R, Liu Z, Xu N, Cao Y, Zhao B, Du J. Vitamin D/VDR signaling inhibits colitis by suppressing HIF-1α activation in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2021;320:G837-46. [PMID: 33759562 DOI: 10.1152/ajpgi.00061.2021] [Reference Citation Analysis]
53 Kosoy R, Kim-Schulze S, Rahman A, Friedman JR, Huang R, Peters LA, Amir EA, Perrigoue J, Stojmirovic A, Song WM, Ke H, Ungaro R, Mehandru S, Cho J, Dubinsky M, Curran M, Brodmerkel C, Schadt EE, Sands BE, Colombel JF, Kasarskis A, Argmann CA, Suárez-Fariñas M. Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy. Cell Mol Gastroenterol Hepatol 2021;12:599-632. [PMID: 33813036 DOI: 10.1016/j.jcmgh.2021.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Ou AT, Zhang JX, Fang YF, Wang R, Tang XP, Zhao PF, Zhao YG, Zhang M, Huang YZ. Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. Acta Pharmacol Sin 2020;42:1913-20. [PMID: 34561552 DOI: 10.1038/s41401-021-00770-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Atreya R. Endoscopy as a Diagnostic Tool for Personalized Therapy in IBD: Prediction of Response to Biological Therapy. Drug Res (Stuttg) 2021;71:S3-4. [PMID: 34788874 DOI: 10.1055/a-1606-4913] [Reference Citation Analysis]
56 Zou M, Zeng QS, Nie J, Yang JH, Luo ZY, Gan HT. The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe? Front Immunol 2021;12:769167. [PMID: 34956195 DOI: 10.3389/fimmu.2021.769167] [Reference Citation Analysis]
57 Hafez HM, Ibrahim MA, Yehia Abdelzaher W, Gad AA, Mohammed Naguib Abdel Hafez S, Abdel-Gaber SA. Protective effect of mirtazapine against acetic acid-induced ulcerative colitis in rats: Role of NLRP3 inflammasome pathway. Int Immunopharmacol 2021;101:108174. [PMID: 34601335 DOI: 10.1016/j.intimp.2021.108174] [Reference Citation Analysis]
58 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Reference Citation Analysis]
59 Xue G, Hua L, Liu D, Zhong M, Chen Y, Zhou B, Xie Y, Li J. Tim-4 expressing monocytes as a novel indicator to assess disease activity and severity of ulcerative colitis. Life Sci 2021;269:119077. [PMID: 33465392 DOI: 10.1016/j.lfs.2021.119077] [Reference Citation Analysis]
60 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Nishikawa H, Nakamura S, Miyazaki T, Kakimoto K, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance. J Clin Med 2021;10:4214. [PMID: 34575326 DOI: 10.3390/jcm10184214] [Reference Citation Analysis]
62 Nag A, Romero B. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease. Health Qual Life Outcomes 2022;20:75. [PMID: 35525935 DOI: 10.1186/s12955-022-01975-1] [Reference Citation Analysis]
63 Sun S, Xu X, Liang L, Wang X, Bai X, Zhu L, He Q, Liang H, Xin X, Wang L, Lou C, Cao X, Chen X, Li B, Wang B, Zhao J. Lactic Acid-Producing Probiotic Saccharomyces cerevisiae Attenuates Ulcerative Colitis via Suppressing Macrophage Pyroptosis and Modulating Gut Microbiota. Front Immunol 2021;12:777665. [PMID: 34899735 DOI: 10.3389/fimmu.2021.777665] [Reference Citation Analysis]
64 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Reference Citation Analysis]
65 Stewart DR. Insights Into Immune-Mediated Disease and Cancer Risk-Delivering on the Promise of UK Biobank Big Data. JAMA Oncol 2021. [PMID: 34854873 DOI: 10.1001/jamaoncol.2021.5572] [Reference Citation Analysis]
66 Xu F, Fei Z, Dai H, Xu J, Fan Q, Shen S, Zhang Y, Ma Q, Chu J, Peng F, Zhou F, Liu Z, Wang C. Mesenchymal Stem Cell-Derived Extracellular Vesicles with High PD-L1 Expression for Autoimmune Diseases Treatment. Adv Mater 2021;:e2106265. [PMID: 34613627 DOI: 10.1002/adma.202106265] [Reference Citation Analysis]
67 Lenert ME, Avona A, Garner KM, Barron LR, Burton MD. Sensory Neurons, Neuroimmunity, and Pain Modulation by Sex Hormones. Endocrinology 2021;162:bqab109. [PMID: 34049389 DOI: 10.1210/endocr/bqab109] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Hoshi N, Inoue J, Sasaki D, Sasaki K. The Kobe University Human Intestinal Microbiota Model for gut intervention studies. Appl Microbiol Biotechnol 2021;105:2625-32. [PMID: 33718974 DOI: 10.1007/s00253-021-11217-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Xu HM, Huang HL, Xu J, He J, Zhao C, Peng Y, Zhao HL, Huang WQ, Cao CY, Zhou YJ, Zhou YL, Nie YQ. Cross-Talk Between Butyric Acid and Gut Microbiota in Ulcerative Colitis Following Fecal Microbiota Transplantation. Front Microbiol 2021;12:658292. [PMID: 33912150 DOI: 10.3389/fmicb.2021.658292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
71 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
72 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
73 Wang K, Ding Y, Xu C, Hao M, Li H, Ding L. Cldn-7 deficiency promotes experimental colitis and associated carcinogenesis by regulating intestinal epithelial integrity. Oncoimmunology 2021;10:1923910. [PMID: 34026335 DOI: 10.1080/2162402X.2021.1923910] [Reference Citation Analysis]
74 Toyonaga T, Saruta M. Role of microRNAs in the Pathophysiology of Ulcerative Colitis. Immuno 2021;1:558-73. [DOI: 10.3390/immuno1040039] [Reference Citation Analysis]
75 Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis 2021:S1590-8658(21)00761-1. [PMID: 34538764 DOI: 10.1016/j.dld.2021.08.020] [Reference Citation Analysis]
76 Gu D, Nan Q, Miao Y, Yang H, Li M, Ye Y, Miao J. KT2 alleviates ulcerative colitis by reducing Th17 cell differentiation through the miR-302c-5p/STAT3 axis. Eur J Cell Biol 2022;101:151223. [PMID: 35405463 DOI: 10.1016/j.ejcb.2022.151223] [Reference Citation Analysis]
77 Chen L, Jing T, Lin Z, Song W, Du W, Fan X, Li C, Li S, Xie F, Ou X, Huang L, Ma J. Metabolomic and transcriptomic responses of mouse testis to the dextran sulfate sodium induced colitis. Reproductive Toxicology 2022;108:35-42. [DOI: 10.1016/j.reprotox.2022.01.005] [Reference Citation Analysis]
78 Wang L, Hu Y, Song B, Xiong Y, Wang J, Chen D. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflamm Res 2021;70:753-64. [PMID: 34212215 DOI: 10.1007/s00011-021-01482-x] [Reference Citation Analysis]
79 Godínez-Méndez LA, Gurrola-Díaz CM, Zepeda-Nuño JS, Vega-Magaña N, Lopez-Roa RI, Íñiguez-Gutiérrez L, García-López PM, Fafutis-Morris M, Delgado-Rizo V. In Vivo Healthy Benefits of Galacto-Oligosaccharides from Lupinus albus (LA-GOS) in Butyrate Production through Intestinal Microbiota. Biomolecules 2021;11:1658. [PMID: 34827656 DOI: 10.3390/biom11111658] [Reference Citation Analysis]
80 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Sultan S, El-Mowafy M, Elgaml A, Ahmed TAE, Hassan H, Mottawea W. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Front Physiol 2021;12:715506. [PMID: 34646151 DOI: 10.3389/fphys.2021.715506] [Reference Citation Analysis]
82 Zhang Z, Yu PF, Gu GL, Zhang YH, Wang YM, Dong ZW, Yang HR. Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature. World J Clin Cases 2022; 10(5): 1729-1737 [DOI: 10.12998/wjcc.v10.i5.1729] [Reference Citation Analysis]
83 Li S, Zhang H, Chen K, Jin M, Vu SH, Jung S, He N, Zheng Z, Lee MS. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges. Drug Deliv 2022;29:1142-9. [PMID: 35384787 DOI: 10.1080/10717544.2022.2058646] [Reference Citation Analysis]
84 Wang Z, Xue R, Lv M, Qi Y, Yu W, Xie Z, Chen W, Wang X, Tian X, Han B. Stepwise tracking strategy to screen ingredient from Galla Chinensis based on the "mass spectrometry guided preparative chromatography coupled with systems pharmacology". J Ethnopharmacol 2021;284:114533. [PMID: 34728319 DOI: 10.1016/j.jep.2021.114533] [Reference Citation Analysis]
85 Wei Q, Xing M, Wang K, Yang Q, Zhao J, Wang Y, Li X, Ji K, Song S. Fucoidan Is Not Completely Dependent on Degradation to Fucose to Relieve Ulcerative Colitis. Pharmaceuticals 2022;15:430. [DOI: 10.3390/ph15040430] [Reference Citation Analysis]
86 Qu Y, Li X, Xu F, Zhao S, Wu X, Wang Y, Xie J. Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis. Front Immunol 2021;12:679897. [PMID: 34367139 DOI: 10.3389/fimmu.2021.679897] [Reference Citation Analysis]
87 Thomas JP, Ölbei M, Brooks-Warburton J, Korcsmaros T, Modos D. Analysing miRNA-Target Gene Networks in Inflammatory Bowel Disease and Other Complex Diseases Using Transcriptomic Data. Genes (Basel) 2022;13:370. [PMID: 35205414 DOI: 10.3390/genes13020370] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Öhman L, Lasson A, Strömbeck A, Isaksson S, Hesselmar M, Simrén M, Strid H, Magnusson MK. Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. Sci Rep 2021;11:8641. [PMID: 33883600 DOI: 10.1038/s41598-021-87973-7] [Reference Citation Analysis]
89 Zhang H, Ding Y, Zeng Q, Wang D, Liu G, Hussain Z, Xiao B, Liu W, Deng T. The characteristics of mesenteric adipose tissue attached to different intestinal segments and their roles in immune regulation. Am J Physiol Gastrointest Liver Physiol 2022. [PMID: 34984923 DOI: 10.1152/ajpgi.00256.2021] [Reference Citation Analysis]
90 Schulz-Kuhnt A, Neurath MF, Wirtz S, Atreya I. Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases. Front Med (Lausanne) 2021;8:656745. [PMID: 33869257 DOI: 10.3389/fmed.2021.656745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Lyu D, Kou G, Li S, Li L, Li B, Zhou R, Yang X, Tian W, Li Y, Zuo X. Digital Spatial Profiling Reveals Functional Shift of Enterochromaffin Cell in Patients With Ulcerative Colitis. Front Cell Dev Biol 2022;10:841090. [DOI: 10.3389/fcell.2022.841090] [Reference Citation Analysis]
92 Guo Y, He X, Zhao RM, Yang HZ, Huang Z, Zhang J, Yu XQ. Zn-Dipicolylamine-based Reactive Oxygen Species-Responsive Lipids for siRNA Delivery and in vivo Colitis Treatment. Acta Biomater 2022:S1742-7061(22)00242-2. [PMID: 35489607 DOI: 10.1016/j.actbio.2022.04.033] [Reference Citation Analysis]
93 Rao K, Qin S, Yang Y, Zhan K, Wu H, Zheng H, Huang S. Shenling Baizhu Powder Alleviates TNBS-Induced Colitis in Rats by Improving Intestinal Epithelial Permeability and Inhibiting Inflammation Through the TLR5/MyD88/NF-κB Pathway. Front Pharmacol 2022;13:883918. [DOI: 10.3389/fphar.2022.883918] [Reference Citation Analysis]
94 Magnusson MK, Vidal A, Maasfeh L, Isaksson S, Malhotra R, Olsson HK, Öhman L. Impaired Butyrate Induced Regulation of T Cell Surface Expression of CTLA-4 in Patients with Ulcerative Colitis. Int J Mol Sci 2021;22:3084. [PMID: 33802979 DOI: 10.3390/ijms22063084] [Reference Citation Analysis]
95 Liu C, Huang S, Wu Z, Li T, Li N, Zhang B, Han D, Wang S, Zhao J, Wang J. Cohousing-mediated microbiota transfer from milk bioactive components-dosed mice ameliorate colitis by remodeling colonic mucus barrier and lamina propria macrophages. Gut Microbes 2021;13:1-23. [PMID: 33789528 DOI: 10.1080/19490976.2021.1903826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Wan Y, Yang L, Jiang S, Qian D, Duan J. Excessive Apoptosis in Ulcerative Colitis: Crosstalk Between Apoptosis, ROS, ER Stress, and Intestinal Homeostasis. Inflamm Bowel Dis 2021:izab277. [PMID: 34871402 DOI: 10.1093/ibd/izab277] [Reference Citation Analysis]
97 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
98 Li S, Jin M, Wu Y, Jung S, Li D, He N, Lee MS. An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice. Drug Deliv 2021;28:1120-31. [PMID: 34121560 DOI: 10.1080/10717544.2021.1934189] [Reference Citation Analysis]
99 Lin Y, Wu Y, Su J, Wang M, Wu X, Su Z, Yi X, Wei L, Cai J, Sun Z. Therapeutic role of d-pinitol on experimental colitis via activating Nrf2/ARE and PPAR-γ/NF-κB signaling pathways. Food Funct 2021;12:2554-68. [PMID: 33625409 DOI: 10.1039/d0fo03139a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Li M, Zhang Y, Ren X, Niu W, Yuan Q, Cao K, Zhang J, Gao X, Su D. Activatable fluorogenic probe for accurate imaging of ulcerative colitis hypoxia in vivo. Chem Commun (Camb) 2021. [PMID: 34928281 DOI: 10.1039/d1cc06577g] [Reference Citation Analysis]
101 Corcoran RM, MacDonagh P, O'Connell F, Morrissey ME, Dunne MR, Argue R, O'Sullivan J, Kevans D. Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour. Dig Dis Sci 2022. [PMID: 35288829 DOI: 10.1007/s10620-022-07411-0] [Reference Citation Analysis]
102 Pan S, Liu R, Wu X, Ma K, Luo W, Nie K, Zhang C, Meng X, Tong T, Chen X, Wang X, Deng M. LncRNA NEAT1 mediates intestinal inflammation by regulating TNFRSF1B. Ann Transl Med 2021;9:773. [PMID: 34268386 DOI: 10.21037/atm-21-34] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
103 Cao Q, Lin Y, Yue C, Wang Y, Quan F, Cui X, Bi R, Tang X, Yang Y, Wang C, Li X, Gao X. IL-6 deficiency promotes colitis by recruiting Ly6Chi monocytes into inflamed colon tissues in a CCL2-CCR2-dependent manner. Eur J Pharmacol 2021;904:174165. [PMID: 33979652 DOI: 10.1016/j.ejphar.2021.174165] [Reference Citation Analysis]
104 Zhang W, Fu X, Xie J, Pan H, Han W, Huang W. miR-26a attenuates colitis and colitis-associated cancer by targeting the multiple intestinal inflammatory pathways. Mol Ther Nucleic Acids 2021;24:264-73. [PMID: 33815939 DOI: 10.1016/j.omtn.2021.02.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Texler B, Zollner A, Reinstadler V, Reider SJ, Macheiner S, Jelusic B, Pfister A, Watschinger C, Przysiecki N, Tilg H, Oberacher H, Moschen AR. Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00192-2. [PMID: 34624526 DOI: 10.1016/j.jcmgh.2021.09.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Chen H, Wu X, Xu C, Lin J, Liu Z. Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. Precision Clinical Medicine 2021;4:246-57. [DOI: 10.1093/pcmedi/pbab025] [Reference Citation Analysis]
107 Palmieri O, Castellana S, Biscaglia G, Panza A, Latiano A, Fontana R, Guerra M, Corritore G, Latiano T, Martino G, Mazza T, Andriulli A, Perri F, Bossa F. Microbiome Analysis of Mucosal Ileoanal Pouch in Ulcerative Colitis Patients Revealed Impairment of the Pouches Immunometabolites. Cells 2021;10:3243. [PMID: 34831464 DOI: 10.3390/cells10113243] [Reference Citation Analysis]
108 Bersuder E, Terciolo C, Lechevrel M, Martin E, Quesnelle C, Freund JN, Reimund JM, Gross I. Mesalazine initiates an anti-oncogenic β-catenin / MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms. Biomed Pharmacother 2021;146:112543. [PMID: 34929577 DOI: 10.1016/j.biopha.2021.112543] [Reference Citation Analysis]
109 Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
110 Chen G, Yang Z, Wen D, Guo J, Xiong Q, Li P, Zhao L, Wang J, Wu C, Dong L. Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis. Immun Inflamm Dis 2021;9:959-70. [PMID: 34010516 DOI: 10.1002/iid3.455] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Zhang L, Yu L, Wei Y. Oral Administration of Cryptotanshinone-Encapsulated Nanoparticles for the Amelioration of Ulcerative Colitis. Cel Mol Bioeng . [DOI: 10.1007/s12195-021-00711-x] [Reference Citation Analysis]
112 Seidelin JB, Bahl MI, Licht TR, Mead BE, Karp JM, Johansen JV, Riis LB, Galera MR, Woetmann A, Bjerrum JT. Acute Experimental Barrier Injury Triggers Ulcerative Colitis-Specific Innate Hyperresponsiveness and Ulcerative Colitis-Type Microbiome Changes in Humans. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00117-X. [PMID: 34118489 DOI: 10.1016/j.jcmgh.2021.06.002] [Reference Citation Analysis]
113 Roselli M, Maruszak A, Grimaldi R, Harthoorn L, Finamore A. Galactooligosaccharide Treatment Alleviates DSS-Induced Colonic Inflammation in Caco-2 Cell Model. Front Nutr 2022;9:862974. [DOI: 10.3389/fnut.2022.862974] [Reference Citation Analysis]
114 Bjerrum JT, Wang YL, Seidelin JB, Nielsen OH. IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine 2021;71:103551. [PMID: 34419930 DOI: 10.1016/j.ebiom.2021.103551] [Reference Citation Analysis]
115 Rao Q, Ma GC, Wu H, Li M, Xu W, Wang GJ, Wang D, Zhang CE, Ma ZJ, Zhang ZT. Dendritic cell combination therapy reduces the toxicity of triptolide and ameliorates colitis in murine models. Drug Deliv 2022;29:679-91. [PMID: 35225120 DOI: 10.1080/10717544.2022.2044935] [Reference Citation Analysis]
116 Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology 2022:S0016-5085(22)00199-8. [PMID: 35227777 DOI: 10.1053/j.gastro.2022.02.033] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
117 Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem 2022; 13(1): 1-14 [DOI: 10.4331/wjbc.v13.i1.1] [Reference Citation Analysis]
118 Maeda K, Nakamura M, Yamamura T, Sawada T, Ishikawa E, Oishi A, Ikegami S, Kakushima N, Furukawa K, Iida T, Mizutani Y, Ishikawa T, Ohno E, Honda T, Ishigami M, Kawashima H. Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis. Biomedicines 2022;10:872. [DOI: 10.3390/biomedicines10040872] [Reference Citation Analysis]
119 Xu X, Li J, Long X, Tao S, Yu X, Ruan X, Zhao K, Tian L. C646 Protects Against DSS-Induced Colitis Model by Targeting NLRP3 Inflammasome. Front Pharmacol 2021;12:707610. [PMID: 34322027 DOI: 10.3389/fphar.2021.707610] [Reference Citation Analysis]
120 Saiki JP, Andreasson JO, Grimes KV, Frumkin LR, Sanjines E, Davidson MG, Park KT, Limketkai B. Treatment-refractory ulcerative colitis responsive to indigo naturalis. BMJ Open Gastroenterol 2021;8:e000813. [PMID: 34969665 DOI: 10.1136/bmjgast-2021-000813] [Reference Citation Analysis]
121 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
122 Brierley SM. Food for thought about the immune drivers of gut pain. Nature 2021;590:41-3. [PMID: 33441989 DOI: 10.1038/d41586-020-03661-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Yu C, Chen T, Lu S, Hu W, Zhang Q, Tan J, Sun D, Li L, Sun X, Xu C, Lai Y, Fan M, Shen Z, Shen W, Cheng H. Identification of Significant Modules and Targets of Xian-Lian-Jie-Du Decoction Based on the Analysis of Transcriptomics, Proteomics and Single-Cell Transcriptomics in Colorectal Tumor. JIR 2022;Volume 15:1483-99. [DOI: 10.2147/jir.s344861] [Reference Citation Analysis]
124 Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol 2021;12:707776. [PMID: 34305614 DOI: 10.3389/fphar.2021.707776] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Qu L, Lin X, Liu C, Ke C, Zhou Z, Xu K, Cao G, Liu Y. Atractylodin Attenuates Dextran Sulfate Sodium-Induced Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting Inflammatory Response Through the MAPK Pathway. Front Pharmacol 2021;12:665376. [PMID: 34335244 DOI: 10.3389/fphar.2021.665376] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Song F, Zhang Y, Pan Z, Hu X, Zhang Q, Huang F, Ye X, Huang P. The role of alcohol dehydrogenase 1C in regulating inflammatory responses in ulcerative colitis. Biochem Pharmacol 2021;192:114691. [PMID: 34293286 DOI: 10.1016/j.bcp.2021.114691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Cao C, Zhu B, Liu Z, Wang X, Ai C, Gong G, Hu M, Huang L, Song S. An arabinogalactan from Lycium barbarum attenuates DSS-induced chronic colitis in C57BL/6J mice associated with the modulation of intestinal barrier function and gut microbiota. Food Funct 2021;12:9829-43. [PMID: 34664587 DOI: 10.1039/d1fo01200b] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Miyake Y, Tanaka K, Nagata C, Furukawa S, Andoh A, Yokoyama T, Yoshimura N, Mori K, Ninomiya T, Yamamoto Y, Takeshita E, Ikeda Y, Saito M, Ohashi K, Imaeda H, Kakimoto K, Higuchi K, Nunoi H, Mizukami Y, Suzuki S, Hiraoka S, Okada H, Kawasaki K, Higashiyama M, Hokari R, Miura H, Miyake T, Kumagi T, Kato H, Hato N, Sayama K, Hiasa Y; Japan Ulcerative Colitis Study Group. IL12B rs6887695 polymorphism and interaction with alcohol intake in the risk of ulcerative colitis in Japan. Cytokine 2022;155:155901. [PMID: 35567898 DOI: 10.1016/j.cyto.2022.155901] [Reference Citation Analysis]
129 Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol 2021;6:429-37. [PMID: 33887262 DOI: 10.1016/S2468-1253(21)00062-5] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Zeng Z, Liew SS, Wei X, Pu K. Hemicyanine-Based Near-Infrared Activatable Probes for Imaging and Diagnosis of Diseases. Angew Chem Int Ed Engl 2021. [PMID: 34263981 DOI: 10.1002/anie.202107877] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
131 Sun L, Han Y, Wang H, Liu H, Liu S, Yang H, Ren X, Fang Y. MicroRNAs as potential biomarkers for the diagnosis of inflammatory bowel disease: a systematic review and meta-analysis. J Int Med Res 2022;50:3000605221089503. [PMID: 35443818 DOI: 10.1177/03000605221089503] [Reference Citation Analysis]
132 Wang X, Memon AA, Palmér K, Hedelius A, Sundquist J, Sundquist K. The association of zonulin-related proteins with prevalent and incident inflammatory bowel disease. BMC Gastroenterol 2022;22:3. [PMID: 34979917 DOI: 10.1186/s12876-021-02075-y] [Reference Citation Analysis]
133 Lin R, Wu W, Chen H, Gao H, Wu X, Li G, He Q, Lu H, Sun M, Liu Z. GPR65 promotes intestinal mucosal Th1 and Th17 cell differentiation and gut inflammation through downregulating NUAK2. Clin Transl Med 2022;12:e771. [PMID: 35343079 DOI: 10.1002/ctm2.771] [Reference Citation Analysis]
134 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Reference Citation Analysis]
135 Cui DJ, Chen C, Yuan WQ, Yang YH, Han L. Integrative analysis of ferroptosis-related genes in ulcerative colitis. J Int Med Res 2021;49:3000605211042975. [PMID: 34510961 DOI: 10.1177/03000605211042975] [Reference Citation Analysis]